Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SI-B001 + SI-B003 plus platinum-based chemotherapy in first-line recurrent or metastatic head and neck squamous cell carcinoma
CTR20244075Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab, SI-B003 in head and neck squamous cell carcinoma (HNSCC), sponsored by Biokin Pharmaceutical. Started Nov 2024; status: active.
02
Drugs
izalontamabSI-B003
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20244075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244075.